Kalaris reports 53-fold lower TH103 plasma peak
Kalaris Therapeutics (NASDAQ:KLRS) reported expanded Phase 1a TH103 data from 20 patients, with plasma exposure up to 53-fold below leading anti-VEGF agents.
Kalaris Therapeutics (NASDAQ:KLRS) reported expanded Phase 1a TH103 data from 20 patients, with plasma exposure up to 53-fold below leading anti-VEGF agents.
ConocoPhillips (NYSE:COP) agreed to acquire a 42% interest in BP’s (NYSE:BP) Kirkuk venture, covering four producing fields and more than 3 billion barrels of oil equivalent.
GSK (NYSE:GSK) ended camlipixant development for chronic cough after CALM-2 missed its primary endpoint at 50mg.
Truist Financial (NYSE:TFC) reported Q2 2026 revenue of $5.23 billion and EPS of $1.08, matching profit expectations but narrowly missing revenue forecasts.
Fifth Third Bancorp (NYSE:FITB) reported Q2 2026 EPS of $0.83 and adjusted EPS of $1.02, supported by organic growth and Comerica integration.
South Plains Financial (NASDAQ:SPFI) reported Q2 net income of $19 million and diluted EPS of $0.96, supported by its BOH acquisition.
Autoliv (NYSE:ALV) reported Q2 net sales of $2.803 billion, up 3.3%, while diluted EPS fell 38% to $1.35.
Regions Financial (NYSE:RF) reported Q2 net income of $549 million and diluted EPS of $0.64, with adjusted earnings of $583 million and adjusted EPS of $0.68.
Netflix (NASDAQ:NFLX) shares fell 9.2% before Friday’s opening bell after its third-quarter revenue and earnings forecasts missed analyst estimates.
Honeywell Technologies (NASDAQ:HON) completed its £1.325 billion all-cash acquisition of Johnson Matthey’s Catalyst Technologies business.
GET YOUR GRAFA EDGE NOW
We'll switch on a 30-day Edge trial as a welcome gift
Got a second for a cookie? 🍪Essential cookies keep Grafa running smoothly. A few optional ones help us see what's working so we can make it better. You're in control — change your mind any time. Cookie policy · Privacy policy